MUMBAI - Dusty roads, poor sanitation, rickety primary health centers, low income levels and sparse availability of qualified doctors - hardly a compelling environment for large pharmaceutical companies to grow their businesses but a few are bracing up to the challenges of the great Indian rural market
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
